June 27, 2024

| To | To |
|---|---|
| Listing Department,<br>**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**<br>Exchange Plaza,<br>Bandra Kurla Complex, Bandra (E),<br>**MUMBAI -400 051**<br><br>**Company Code No. AUROPHARMA** | The Corporate Relations Department<br>**BSE LIMITED**<br>Phiroz Jeejeebhoy Towers,<br>Dalal Street,<br>**MUMBAI -400 001**<br><br>**Company Code No. 524804** |

Dear Sir / Madam,

**Sub: Classification of US FDA Inspection at the injectable facility of Eugia SEZ Pvt. Ltd. – Reg.,**

**Ref : Our letter dated February 29, 2024**

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The U.S. Food and Drug Administration (FDA) had conducted an inspection at the injectable facility of Eugia SEZ Pvt. Ltd. (a 100% step-down subsidiary of Aurobindo Pharma Ltd.), situated at Polepally Village, Jadcherla Mandal, Mahaboobnagar District, Telangana, from February 19 to February 29, 2024.

The Unit has now received Establishment Inspection Report classifying the facility as "Voluntary Action Indicated" ("VAI").

Please take the above information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

BADDIGAM ADI REDDY
Digitally signed by BADDIGAM ADI REDDY
Date: 2024.06.27 11:36:26 +05'30'

B Adi Reddy
Company Secretary